BACKGROUND: New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment. METHODS: We undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants receivedisoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15-20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with ClinicalTrials.gov, number NCT00082173. FINDINGS:74 patients assigned to themoxifloxacingroup and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17.2%, 95% CI 2.8-31.7; p=0.03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group). INTERPRETATION:Moxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified.
RCT Entities:
BACKGROUND: New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolonemoxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment. METHODS: We undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants received isoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15-20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with ClinicalTrials.gov, number NCT00082173. FINDINGS: 74 patients assigned to the moxifloxacin group and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17.2%, 95% CI 2.8-31.7; p=0.03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group). INTERPRETATION:Moxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified.
Authors: J L Johnson; D J Hadad; W H Boom; C L Daley; C A Peloquin; K D Eisenach; D D Jankus; S M Debanne; E D Charlebois; E Maciel; M Palaci; R Dietze Journal: Int J Tuberc Lung Dis Date: 2006-06 Impact factor: 2.373
Authors: William J Burman; Stefan Goldberg; John L Johnson; Grace Muzanye; Melissa Engle; Ann W Mosher; Shurjeel Choudhri; Charles L Daley; Sonal S Munsiff; Zhen Zhao; Andrew Vernon; Richard E Chaisson Journal: Am J Respir Crit Care Med Date: 2006-05-04 Impact factor: 21.405
Authors: N Lounis; A Bentoucha; C Truffot-Pernot; B Ji; R J O'Brien; A Vernon; G Roscigno; J Grosset Journal: Antimicrob Agents Chemother Date: 2001-12 Impact factor: 5.191
Authors: Debra Benator; Mondira Bhattacharya; Lorna Bozeman; William Burman; Antonino Cantazaro; Richard Chaisson; Fred Gordin; C Robert Horsburgh; James Horton; Awal Khan; Christopher Lahart; Beverly Metchock; Constance Pachucki; Llewellyn Stanton; Andrew Vernon; M Elsa Villarino; Yong Chen Wang; Marc Weiner; Stephen Weis Journal: Lancet Date: 2002-08-17 Impact factor: 79.321
Authors: Roly D Gosling; Leonard O Uiso; Noel E Sam; Emily Bongard; Esther G Kanduma; Mramba Nyindo; Richard W Morris; Stephen H Gillespie Journal: Am J Respir Crit Care Med Date: 2003-08-13 Impact factor: 21.405
Authors: R Rustomjee; C Lienhardt; T Kanyok; G R Davies; J Levin; T Mthiyane; C Reddy; A W Sturm; F A Sirgel; J Allen; D J Coleman; B Fourie; D A Mitchison Journal: Int J Tuberc Lung Dis Date: 2008-02 Impact factor: 2.373
Authors: Laura Y Park-Wyllie; David N Juurlink; Alexander Kopp; Baiju R Shah; Therese A Stukel; Carmine Stumpo; Linda Dresser; Donald E Low; Muhammad M Mamdani Journal: N Engl J Med Date: 2006-03-01 Impact factor: 91.245
Authors: Rokeya Tasneen; Si-Yang Li; Charles A Peloquin; Dinesh Taylor; Kathy N Williams; Koen Andries; Khisimuzi E Mdluli; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2011-09-19 Impact factor: 5.191
Authors: Marc Weiner; Thomas J Prihoda; William Burman; John L Johnson; Stefan Goldberg; Nesri Padayatchi; Paula Duran; Melissa Engle; Grace Muzanye; Roy D Mugerwa; A Willem Sturm Journal: J Clin Microbiol Date: 2010-10-06 Impact factor: 5.948
Authors: Si-Yang Li; Scott M Irwin; Paul J Converse; Khisi E Mdluli; Anne J Lenaerts; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2015-04-27 Impact factor: 5.191
Authors: Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405